NYSE · A
Agilent Technologies, Inc.
$181.15-$0.33 (-0.18%)
Agilent Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.01% below the high.
Loading market information…
NASDAQ · TXG · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
10x Genomics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.68% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
10x Genomics, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.27. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow 10x Genomics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 8, 2025 | -$0.36+20.0% vs estimate | $154.88M+6.62% vs estimate |
|---|
| Q4 2024 | Feb 12, 2025 | -$0.40-37.93% vs estimate | $165.02M+0.02% vs estimate |
|---|
| Q3 2024 | Oct 29, 2024 | -$0.30+11.76% vs estimate | $151.65M-1.09% vs estimate |
|---|
THE ANALYST VIEW
22 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 10 contributors · Median target $75.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$181.15-$0.33 (-0.18%)
Agilent Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.01% below the high.
$290.06+$1.27 (+0.44%)
Illumina, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.24% below the high.
$165.78+$0.45 (+0.27%)
Revvity, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.94% below the high.
$173.45$0.00 (0.0%)
Twist Bioscience Corporation’s quoted price sits in the upper half of its reported 52-week range, 21.06% below the high.
$72.71+$0.02 (+0.03%)
Bio-Techne Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
$50.34+$0.01 (+0.02%)
Qiagen N.V.’s quoted price sits in the upper half of its reported 52-week range, 12.94% below the high.
$384.40-$0.72 (-0.19%)
Bio-Rad Laboratories, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.99% below the high.
HK$34.62-HK$3.08 (-8.17%)
Genscript Biotech Corporation’s quoted price sits in the upper half of its reported 52-week range, 29.76% below the high.
